Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology APIs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107935997A reveals a cost-effective Osimertinib route avoiding expensive chloropyrimidine. Enhance supply chain reliability with scalable manufacturing.
Patent CN114181132A reveals a novel high-purity synthesis route for nintedanib intermediates, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN110777391B reveals a green electroreduction method for gefitinib intermediates, offering high purity, reduced costs, and scalable manufacturing for global pharmaceutical supply chains.
Patent CN111138492B details a high-yield Brigatinib synthesis avoiding column chromatography. This report analyzes cost reduction and supply chain reliability for API manufacturing.
Patent CN102010455B reveals a novel Decitabine synthesis avoiding isomer separation. High purity >99.85% via Barton-McCombie deoxygenation for cost-effective manufacturing.
Discover the optimized synthesis of quinoline angiogenesis inhibitors via CN102356063A. Enhance purity and safety in pharmaceutical intermediate manufacturing.
Patent CN112250639B details a novel Ru/Cu-catalyzed route for heterocyclic arylamines. Discover cost-effective manufacturing and high-purity supply chain solutions.
Advanced convergent synthesis for Gefitinib intermediates eliminating chromatography. High-purity API manufacturing solutions for global pharmaceutical supply chains.
Novel synthesis of Erlotinib HCl via 3,4-dihydroxybenzaldehyde avoids demethylation steps, offering cost-effective industrial scale-up for pharmaceutical intermediates.
Advanced synthesis of 3-aminopiperidine-2,6-dione hydrochloride via L-glutamic acid cyclization. Offers superior purity, reduced toxicity, and cost-effective scaling for pharmaceutical supply chains.
Advanced synthesis of Gefitinib intermediates via CN102146060A. Eco-friendly route eliminates halogenating agents, ensuring high purity and cost reduction in API manufacturing.
Patent CN110747489B reveals a novel electroreduction method for 2-amino-4-methoxybenzoic acid derivatives, offering high-purity intermediates for Gefitinib with reduced environmental impact.
Patent CN112469711A reveals a high-purity synthesis route for quinoline derivatives, eliminating column chromatography and reducing impurities for scalable API intermediate manufacturing.
Novel preparation method of Bosutinib avoiding hazardous chlorinating agents. Offers cost reduction in API manufacturing and reliable supply chain solutions.
Advanced synthesis of Belinostat intermediate II via safe esterification and HWE reactions. Reduces hazards and costs for HDAC inhibitor manufacturing.
Patent CN103864878A reveals a novel cross-coupling method for Abiraterone Acetate using organozinc reagents, offering significant cost reduction and improved purity for pharmaceutical intermediates manufacturing.
Patent CN113024518A details a streamlined 3-step halogenation route for Erdafitinib, offering high purity and reduced costs for pharmaceutical manufacturers.
Patent CN100564365C details a streamlined 2-step synthesis for Anastrozole, offering superior purity and cost efficiency for pharmaceutical manufacturing.
Patent CN104447739B details deuterated Palbociclib derivatives enhancing bioavailability. We offer scalable synthesis for reliable API intermediate supply chains.
Novel catalytic hydrogenation route for Lenalidomide. High purity, reduced solvent use, scalable manufacturing for API intermediates.